Real-World Results of Different Devices for TAVR

Transcatheter aortic valve replacement (TAVR) keeps growing in terms of the development of new devices, more extensive operator experience, and enhanced procedure planning. Nowadays, there are multiple device options, which depend on patient characteristics and operator experience. Two-arm studies compared these devices, analyzing the potential benefits of a certain valve over the others.

dispositivos para TAVI en el mundo real

This multicenter prospective study aims to simultaneously compare the results of the most popular second- and third-generation transcatheter aortic valves in a real-world population.

The primary endpoint was a composite of all-cause death, stroke, and rehospitalization for heart failure at 1 year. The secondary endpoint were the individual components of the primary endpoint and permanent pacemaker implantation and acute myocardial infarction (AMI) at 1 year.

A total of 2728 patients were included in the OBSERVANT II (Observational Study of Effectiveness of TAVI with New Generation Devices for Severe Aortic Stenosis Treatment) study, which was conducted in Italy. The valves compared in the study were EVOLUT R, EVOLUT PRO, SAPIEN 3, ACURATE neo, and PORTICO. Mean patient age was 83 years old, and most subjects were female. The EUROScore II was 5.1 %. Transfemoral access was used the most, in 91 % of the cases.

Read also: We Should Treat Significant Stable CAD in Patients Undergoing TAVR.

Regarding the primary endpoint at 1 year, no differences were reported among the different valve groups (P = 0.56). However, peacemaker implantation was significantly lower at 1 year for patients who received a SAPIEN 3 device (P < 0.01). Moreover, patients with a SAPIEN 3 valve had lower paravalvular leak rates (P < 0.01) and greater transvalvular gradient after TAVR (P <0.01).

Conclusion 

Results from “real-world” practice show lower rates of complications after TAVR for all currently available devices. Patients receiving a SAPIEN 3 valve had lower rates of permanent pacemaker implantation and of paravalvular leak, even though they also had greater transvalvular gradient. In order to confirm these results, larger studies with longer follow-up terms are required.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Real-World Multiple Comparison of Transcatheter Aortic Valves: Insights From the Multicenter OBSERVANT II Study.

Reference: Giuliano Costa et al Circ Cardiovasc Interv. 2022;15:e012294.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...